Institutional members access full text with Ovid®

Share this article on:

TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY

Chung, Yoo-Ri, MD, PhD*; Kim, Jong Wan, MD*; Song, Ji Hun, MD, PhD*; Park, Aram, MD*; Kim, Min Ho, MD

doi: 10.1097/IAE.0000000000001917
Original Study: PDF Only

Purpose: To evaluate intravitreal bevacizumab (IVB) injection efficacy for the treatment of chronic, atypical, or recurrent central serous chorioretinopathy (CSC).

Methods: Clinical data from 77 eyes of 71 patients with chronic, atypical, or recurrent CSC treated with IVB were retrospectively analyzed. After initial 6-weekly IVB administration until no subretinal fluid remained at the fovea, additional as-needed IVBs were administered, based on optical coherence tomography findings. Best-corrected visual acuity and central retinal thickness (CRT) were analyzed at baseline and 3, 6, 9, and 12 months after initial IVB.

Results: The significant improvement of baseline logarithm of minimum angle of resolution best-corrected visual acuity and CRT at 3 months (both P < 0.001) was maintained throughout the 12-month follow-up period. Best-corrected visual acuity improved significantly in patients with chronic and recurrent CSC, at all time points (all P < 0.05), but not in patients with atypical CSC. The CRT reduction was significant in all subgroups during the follow-up period (all P < 0.05). Definite leakage on initial fluorescein angiography correlated with improved reduction in CRT (P = 0.039).

Conclusion: As-needed optical coherence tomography–based IVB was effective for reducing CRT in patients with chronic, atypical, or recurrent CSC, and for vision improvement in chronic and recurrent CSC over the 1-year follow-up period.

This retrospective case series showed that initial repeated and subsequent, as-needed, intravitreal bevacizumab injection was effective for anatomical and functional improvement in patients with chronic, atypical, or recurrent central serous chorioretinopathy for 12 months.

*Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea; and

Department of Ophthalmology, Armed Forces Capital Hospital, Seongnam, Republic of Korea.

Reprint requests: Ji Hun Song, MD, PhD, Department of Ophthalmology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Republic of Korea; e-mail: dreyesong@naver.com

Presented in part as a poster at the 2015 Annual Meeting of the American Academy of Ophthalmology (AAO), Las Vegas, NV, November 14–17, 2015.

None of the authors has any financial/conflicting interests to disclose.

Y.-R. Chung and J. W. Kim contributed equally to this work.

© 2018 by Ophthalmic Communications Society, Inc.